Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID‐19-Reference-Cited by-同舟云学术

Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID‐19

Published:2023-04 Issue:2 Volume:11 Page:
ISSN:2052-1707
Container-title:Pharmacology Research & Perspectives
language:en
Short-container-title:Pharmacology Res & Perspec

Author:

Rothlin Rodolfo Pedro¹^ORCID,Pelorosso Facundo Germán²,Duarte Mariano³⁴,Nicolosi Liliana⁵,Ignacio Fernandez Criado⁶,Salgado María Victoria⁷⁸,Vetulli Héctor⁹

Affiliation:

1. Sociedad Argentina de Farmacología Clínica, Asociación Médica Argentina Buenos Aires Argentina

2. Servicio de Anatomía Patológica Hospital de Alta Complejidad El Calafate SAMIC Santa Cruz Argentina

3. Laboratorio de Hipertensión, División de Cardiología, Hospital de Clínicas "José de San Martín", Facultad de Medicina Universidad de Buenos Aires Buenos Aires Argentina

4. Segunda Cátedra de Fisiología, Facultad de Medicina Universidad de Buenos Aires Buenos Aires Argentina

5. División de Cardiología Hospital Español de Buenos Aires Buenos Aires Argentina

6. Sección de Tecnología Educativa e Informática Médica, Hospital de Clínicas "José de San Martín", Facultad de Medicina Universidad de Buenos Aires Buenos Aires Argentina

7. Centro de Estudios de Estado y Sociedad, Ciudad Autónoma de Buenos Aires Buenos Aires Argentina

8. Servicio de Medicina Familiar Hospital de Alta Complejidad El Calafate SAMIC Santa Cruz Argentina

9. Servicio de Electrofisiología Cardíaca, Arritmias y Marcapasos, Sanatorio Otamendi y Miroli, Ciudad Autónoma de Buenos Aires Buenos Aires Argentina

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,Neurology

Link

https://bpspubs.onlinelibrary.wiley.com/doi/pdf/10.1002/prp2.1083

Reference33 articles.

1. Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics

2. Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID ‐19

3. Potential of angiotensin II receptor blocker telmisartan in reducing mortality among hospitalized patients with COVID-19 compared with recommended drugs

4. Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial

5. Efficacy of Losartan in Hospitalized Patients With COVID-19–Induced Lung Injury

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structural Features Influencing the Bioactive Conformation of Angiotensin II and Angiotensin A: Relationship between Receptor Desensitization, Addiction, and the Blood–Brain Barrier;International Journal of Molecular Sciences;2024-05-26

2. RAAS inhibitors in COVID-19: Not all are created equal. Telmisartan is the one;Revista Portuguesa de Cardiologia;2023-11

3. Assessing the outcomes of prescribing angiotensin converting enzyme inhibitors and angiotensin receptor blockers for COVID-19 patients;Heliyon;2023-09